The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: A randomized controlled pilot trial

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages 396-401

  Makarov, Leonid ^a   Balykova, Larisa ^b   Soldatova, Olga ^b   Komolyatova, Vera ^a   Serebruany, Victor ^c  

^a FEDERAL BIOMEDICAL AGENCY OF RUSSIA   (Russian Federation)

^b OGAREV MORDOVIA STATE UNIVERSITY   (Russian Federation)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

amiodarone; antiarrhythmic agents; pediatrics; quifanidine; randomized trial

Indexed keywords

AMIODARONE; QUIFENADINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BENZHYDRYL DERIVATIVE;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR DISSOCIATION; BRADYCARDIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EYE INJURY; FOLLOW UP; HEART RATE; HEART RHYTHM; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; PILOT STUDY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINUS NODE; SUPRAVENTRICULAR PREMATURE BEAT; TACHYCARDIA; THYROID DISEASE; TREATMENT DURATION; ADOLESCENT; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; VENTRICULAR PREMATURE COMPLEXES;

ADOLESCENT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BENZHYDRYL COMPOUNDS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HISTAMINE ANTAGONISTS; HUMANS; MALE; PILOT PROJECTS; VENTRICULAR PREMATURE COMPLEXES;

EID: 77955011264     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181a86987     Document Type: Article

References (26)

1. Perry J. Pharmacologic therapy of arrhythmias. In: Deal B, Wolf G, Gelband H, eds. Current concepts in diagnosis and management of arrhythmias in infants and children. New York, NY: Futura Pbl Co.; 1998:267-305.
2. Bink-Boelkens MTh. Pharmacologic management of arrhythmia. Pediatric Cardiol. 2000;21:508-515.
3. Conway E, Musco S, Kowey PR. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol. 2008;102:12H-19H.
4. Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6:228-236.
5. Mindel JS. Amiodarone and optic neuropathy. Am Heart J. 2008;156:411-413.
6. Hammwöhner M, Smid J, Lendeckel U, et al. New drugs for atrial fibrillation. J Interv Cardiol Electrophysiol. 2008;23: 15-21.
7. Steiner C, Wit A, Weiss M, et al. The antiarrhythmic actions of carbamezepine (Tegretol). J Pharmacol Exp Ther. 1970;173:323-325.
8. DeSilvey DL, Moss AJ. Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. Ann Intern Med. 1980;93:53-54.
9. Carmeliet E, Xhonneux R, Van Glabbeek A, et al. Electrophysiological effects of droperidol in different cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol. 1976;293:57-66.
10. Vaughan-Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E, Flenset-Jensen E, Olsen K, eds. Cardiac arrhythmias. Sodertalje, Sweden: Astra; 1970:449-472.
11. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 1996;36:233-252.
12. Doenicke A, Moss J, Toledano A, et al. Administration of H1 and H2 antagonists for chemoprophylaxis: a doubleblind, placebo-controlled study in healthy volunteers. J Clin Pharmacol. 1997;37:140-146.
13. Duda D, Lorenz W, Menke H, et al. Perioperative nonspecific histamine release: a new classification by aetiological mechanisms and evaluation of their clinical relevance. Ann Fr Anesth Reanim. 1993;12:147-165.
14. Risk of QT prolongation and torsades de pointes with antihistamines. In: Camm J, Malik M, eds. Acquired long QT syndrome. 1st ed. Baltimore, MD: Blackwell Futura; 2004:87-101.
15. Zhang M-Q. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem. 1997;4:171-178.
16. Craft TM. Torsades de pointes after astemizole overdose. BMJ. 1986;292:660.
17. Stone PH. ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: clinical significance and analytic techniques. Ann Noninvasive Electrocardiol. 2000;10:263-278.
18. Ko CM, Ducic I, Fan J, et al. Suppression of mammalian K+ channel family by ebastine. J Pharmacol Exp Ther. 1997; 281:233-244.
19. Fisas MA, Gutiérrez B, Fort M, et al. General pharmacological profile and effects of E-4716, a novel histamine receptor blocker, on the central nervous system. Methods Find Exp Clin Pharmacol. 1998;20:199-210.
20. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 1996;36:233-252.
21. Crumb WJ Jr, Wible B, Arnold DJ, et al. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadineassociated cardiotoxicity. Mol Pharmacol. 1995;47:181-190.
22. Mashkovsky MD, Yakhontov LN, Kaminka ME, et al. Further developments in research on the chemistry and pharmacology of synthetic quinuclidine derivatives. Prog Drug Res. 1983;27:9-61.
23. Berul CI, Morad M. Regulation of potassium channels by non-sedating antihistamines. Circulation. 1995;91:2220-2225.
24. Assanasen P, Naclerio RM. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin Allergy Immunol. 2002;17:101-139.
25. Galenko-Iaroshevski PA, Cherednik IL, et al. Bartashevich VV, Comparative evaluation of the anti-arrhythmia efficacy of fencarol and dimebon during neurogenic atrial fibrillation. Biull Eksp Biol Med (Moscow). 1997;124: 81-85.
26. Iakovlev GM, Skorobogatov VI, Svistov AS, et al. The experimental anti-arrhythmia properties of the histamine H1 receptor blockader fencarol. Farmakol Toksikol (Moscow). 1991;54:25-27.